Immunocore (NASDAQ:IMCR) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Immunocore (NASDAQ:IMCR) in a research report released on Friday,Benzinga reports. HC Wainwright currently has a $100.00 price target on the stock. HC Wainwright also issued estimates for Immunocore’s FY2027 earnings at $1.10 EPS, FY2028 earnings at $4.46 EPS and FY2029 earnings at $7.96 EPS.

A number of other research analysts have also weighed in on IMCR. Needham & Company LLC reaffirmed a “buy” rating and set a $71.00 price objective on shares of Immunocore in a research report on Thursday. Morgan Stanley reiterated an “equal weight” rating and set a $35.00 target price (down from $74.00) on shares of Immunocore in a research note on Friday, December 13th. Finally, Mizuho downgraded Immunocore from an “outperform” rating to a “neutral” rating and cut their target price for the company from $72.00 to $38.00 in a research note on Monday, November 11th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Immunocore currently has a consensus rating of “Moderate Buy” and an average price target of $65.64.

Immunocore Stock Down 0.7 %

IMCR stock opened at $29.37 on Friday. Immunocore has a twelve month low of $27.69 and a twelve month high of $72.05. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. The firm has a market cap of $1.47 billion, a PE ratio of -30.92 and a beta of 0.77. The business has a 50 day moving average of $30.08 and a 200 day moving average of $31.89.

Institutional Investors Weigh In On Immunocore

Several large investors have recently made changes to their positions in IMCR. Wellington Management Group LLP increased its holdings in shares of Immunocore by 10.5% in the third quarter. Wellington Management Group LLP now owns 7,048,833 shares of the company’s stock worth $219,430,000 after purchasing an additional 668,382 shares during the last quarter. Groupama Asset Managment bought a new stake in shares of Immunocore in the fourth quarter worth about $17,700,000. Primecap Management Co. CA increased its holdings in shares of Immunocore by 26.7% in the third quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company’s stock worth $76,954,000 after purchasing an additional 520,950 shares during the last quarter. Deep Track Capital LP bought a new stake in shares of Immunocore in the fourth quarter worth about $15,322,000. Finally, Tang Capital Management LLC increased its holdings in shares of Immunocore by 40.7% in the fourth quarter. Tang Capital Management LLC now owns 1,555,600 shares of the company’s stock worth $45,890,000 after purchasing an additional 450,000 shares during the last quarter. 84.50% of the stock is owned by institutional investors.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.